chrisvoncsefalvay/vaers-outcomes huggingface dataset:
red and hot around injection site.; Left side of face was red and warm; palpitations; red and hot around injection site.; injection site about 3 and half inches; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (red and hot around injection site.), ERYTHEMA (Left side of face was red and warm), PALPITATIONS (palpitations), VACCINATION SITE ERYTHEMA (red and hot around injection site.) and VACCINATION SITE SWELLING (injection site about 3 and half inches) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21a) for COVID-19 vaccination.     Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN), GABAPENTIN, INHALER, LOSARTAN POTASSIUM (LOSARTIN), OMEPRAZOLE, PANTOPRAZOLE, PROGESTERONE, CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000) and Zertic for an unknown indication.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Apr-2021, the patient experienced VACCINATION SITE WARMTH (red and hot around injection site.), ERYTHEMA (Left side of face was red and warm), PALPITATIONS (palpitations), VACCINATION SITE ERYTHEMA (red and hot around injection site.) and VACCINATION SITE SWELLING (injection site about 3 and half inches). At the time of the report, VACCINATION SITE WARMTH (red and hot around injection site.), ERYTHEMA (Left side of face was red and warm), PALPITATIONS (palpitations), VACCINATION SITE ERYTHEMA (red and hot around injection site.) and VACCINATION SITE SWELLING (injection site about 3 and half inches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided
fever, chills, shakiness, nausea, joing pain, overall teirdness/feeling of sickness
20feb90 pt vax 2nd vax hepta B. 21feb90 pt ex severe weakness and myalgia in the left arm and was unable to perform certain work related functions.  weakness resolved.
pt started vomiting next day of shots -about 4 times; pt taken to ER on 25AUG92 & was given medication stop vomiting; running a fever of 101-pt is teething; mom stated that pt acts like feels OK is playing & eating as usual;
Initial misuse report received from a healthcare professional on 22 July 2013. A patient had received ACT-HIB component of PENTACEL vaccine inadvertently reconstituted with sterile water. The patient did not received DTAP/IPV component of PENTACEL. No information was provided regarding the patient. No adverse event was reported. Documents held by sender: None.
Patient complain of swelling to right arm after receiving immunization. Assessment: Extensive swelling noted to right arm, shoulder to elbow and warm to touch.
Coughing started; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Coughing started) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001B21A and 031M20A) for COVID-19 vaccination.     Concurrent medical conditions included Bronchiectasis (Patient has a history of bronchiectasis without Cystic Fibrosis.) since 07-Jan-2017, Fibrillation atrial since 01-Jan-2020, Penicillin allergy (Hives as a reaction.), Sulfonamide allergy (Hives as a reaction.) and Drug allergy (Allergic to Ceclor . Hives as a reaction.). Concomitant products included ALBUTEROL [SALBUTAMOL] from 07-Jan-2017 to an unknown date for Bronchiectasis, ALLOPURINOL, APIXABAN (ELIQUIS) and AMLODIPINE for an unknown indication.   On 10-Feb-2021 at 10:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021 at 10:30 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COUGH (Coughing started). At the time of the report, COUGH (Coughing started) had not resolved.            No treatment medications were provide by reporter.  Patient started coughing about 2-3 months after receiving the Moderna covid-19 vaccine. She reportedly had a persistent cough secondary to non-cystic fibrosis bronchiectasis. Per report, the patient had a period of relief from coughing between the first and second doses of the vaccine. However, her cough progressively worsened to its pre-vaccination intensity within 3 months of receiving her second dose vaccination. The patient is concomitantly taking other unspecified medications.  Patient has a history of hives as a reaction to drug allergies including penicillin, sulfonamides, and cefaclor.       Most recent FOLLOW-UP information incorporated above includes: On 02-Jul-2021: Follow-up included updated information regarding patient demographics, facility type, medical history, suspect product details like batch number, route of administration, anatomical location, added concomitant medications,  outcome of the event cough updated to recovered. On 09-Jul-2021: Follow-up information received to include updates on reaction for allergies, outcome of the event cough was update from recovered  to not recovered.
Patients' arm was red and warm to touch in deltoid area.  Patient c/o soreness of the area and slight swelling was noted (all at the site of injection).  Injection was in arm (do not know which arm).
12 days after receiving MMR vaccination on 7/1/03 had left knee and hip pain and stiffness. Her doctor said it was an arthritis from the MMR shot. Pain lasted for 3 weeks then resolved.
I got a similar bilateral periorbital dermatitis with real COVID 12/22, had to get new bivalent booster for work.  I have the exact same bilateral periorbital dermatitis 5 days after the vaccine w/o new medication, soaps etc
Information has been received from a consumer concerning her daughter with no known medical history or allergies who in October 2005 was vaccinated IM in the gluteal muscle with a dose of Varivax. Concomitant vaccination included a dose of MMR II. Subsequently, the patient experienced spots on her stomach and behind the ears. Unspecified medical attention was sought. Subsequently the patient recovered. There was no product quality complaint involved. Additional information has been requested.
fatigue; slight fever; had itching on her chest and face area; hives on her chest and face area; swelling at the injection site; pain at the injection site; had redness at the injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a 56-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in left arm on 28th August 2020).   On 16th January 2021, the patient received the 2nd dose of Shingrix. On 16th January 2021, 1 hr after receiving Shingrix, the patient experienced itching and hives. On 17th January 2021, the patient experienced fatigue and fever. On an unknown date, the patient experienced injection site swelling, injection site pain and injection site erythema. The patient was treated with diphenhydramine hydrochloride (Benadryl). On 18th January 2021, the outcome of the fatigue and fever were recovered/resolved. On an unknown date, the outcome of the injection site swelling, injection site pain, injection site erythema, itching and hives were recovered/resolved.   It was unknown if the reporter considered the injection site swelling, injection site pain, injection site erythema, itching, hives, fatigue and fever to be related to Shingrix.  Additional details were reported as follows: This case was reported by patient herself. The patient received 2nd dose of Shingrix in her left arm and less than 2 months after receiving Shingrix, the patient had redness, pain and swelling at the injection site which lasted for a week and then resolved. The patient after about one hour of vaccination had itching and hives on her chest and face area, which resolved as soon as she took Benadryl. The patient had slight fever and fatigue the day after the 2nd dose of the Shingrix and was resolved the next day. The reporter consented to follow-up.
Swollen lymph nodes in her arm; There's also some in her neck and clavicle area; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE LYMPHADENOPATHY (Swollen lymph nodes in her arm) and LYMPHADENOPATHY (There's also some in her neck and clavicle area) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE LYMPHADENOPATHY (Swollen lymph nodes in her arm) and LYMPHADENOPATHY (There's also some in her neck and clavicle area). At the time of the report, VACCINATION SITE LYMPHADENOPATHY (Swollen lymph nodes in her arm) and LYMPHADENOPATHY (There's also some in her neck and clavicle area) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.  No concomitant medication was provided.
vaccine administered after beeing in the fridge for 40 days; it had been stored in the fridge for 40 days so 10 days over our recommended storage.; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine administered after beeing in the fridge for 40 days) and PRODUCT STORAGE ERROR (it had been stored in the fridge for 40 days so 10 days over our recommended storage.) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040C21A) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised.    On 31-Aug-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine administered after beeing in the fridge for 40 days) and PRODUCT STORAGE ERROR (it had been stored in the fridge for 40 days so 10 days over our recommended storage.). On 31-Aug-2021, EXPIRED PRODUCT ADMINISTERED (vaccine administered after beeing in the fridge for 40 days) and PRODUCT STORAGE ERROR (it had been stored in the fridge for 40 days so 10 days over our recommended storage.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant and Treatment was not specified.; Sender's Comments: This report refers to a case of product storage error and expired product administered for mRNA-1273 (batch no. 040C21A)  with no associated AEs.
warmness at injection site; itchiness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE WARMTH (warmness at injection site) and INJECTION SITE PRURITUS (itchiness at injection site) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Mar-2021, the patient experienced INJECTION SITE WARMTH (warmness at injection site) and INJECTION SITE PRURITUS (itchiness at injection site). At the time of the report, INJECTION SITE WARMTH (warmness at injection site) and INJECTION SITE PRURITUS (itchiness at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.   Treatment information was not provided.
numbness to both arms, swelling to lips, itchiness to legs, chest and abdomen.
Information has been received from a nurse via a pharmacist concerning a 40 year old female who was vaccinated with measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation). There was no concomitant medication. Subsequently the pt experienced joint pain. The pt did seek medical attention. Additional info has been requested.
Bilateral low frequency hearing loss- reported by patient. Mild improvement within 3 days. He has been referred for urgent hearing test and ENT referral. Additional testing, treatment and outcome are to be determined.
rash; swollen lips; tongue itching; tongue felt scolded; hives; This spontaneous case was reported by a health care professional and describes the occurrence of LIP SWELLING (swollen lips), TONGUE PRURITUS (tongue itching), ORAL CONTUSION (tongue felt scolded), URTICARIA (hives) and RASH (rash) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Feb-2021, the patient experienced LIP SWELLING (swollen lips), TONGUE PRURITUS (tongue itching), ORAL CONTUSION (tongue felt scolded) and URTICARIA (hives). On 17-Feb-2021, the patient experienced RASH (rash). At the time of the report, LIP SWELLING (swollen lips), TONGUE PRURITUS (tongue itching), ORAL CONTUSION (tongue felt scolded), URTICARIA (hives) and RASH (rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment taken was Medrol dose pack and Benadryl . Concomitant product use was not provided by the patient.
Soreness in the arm the shot was administered to for roughly 24 hours following the shot. Starting at roughly 5 am the day after the shot aching throughout the body along with a fever (unknown temp.) for roughly 12 hours.
Induration, swelling, and erythema developed six hrs post administration( 8cm x 6cm)._
One month after the vaccine, Pt was to come for a follow-up of health concerns. It was then that the "adverse event" was reported to us. She reports fever (100.3), sore throat, fatigue, headache. She went to see primary care where she was diagnosed with tonsillitis and pharyngitis. Tonsils reportedly +4.  She was started on an antibiotic. No GI symptoms.  No localized reaction at the injection site.
Rash the size of a silver dollar at the injection site. Patient not in any discomfort.
This spontaneous report as received from a medical assistant, refers to an unknown number of patients of unknown demographics. Patients' pertinent medical history, concurrent condition and concomitant medication were not reported. No previous drug reactions/allergies were reported. On unknown dates, for the past two years, the patients were vaccinated with improperly stored doses of ZOSTAVAX (strength, dosing details, anatomical location, lot# and expiration date were unknown) for prophylaxis. The vaccine was reconstituted with Sterile Merck Diluent. The Medical assistant refused to provide any additional information including excursion details. No PQC was filed. This is one of the several reports received from the same reporter. Sender's Comments: US-009507513-1709USA000103: US-009507513-1708USA013798.
Patient developed sore arm muscle. Her arm became hard and hot to the touch from shot to shoulder. She awoke Saturday night with shooting pains in her arm and had a fever of 102 degrees. She saw a physician on 11/19/00 and was told she had an infection. She was treated with ibuprofen and cephalexin.
DIDN'T FEEL LIKE MYSELF, EXTREMELY TIRED, HEADACHE, COULD NOT CONCENTRATE
her arm became warm to the touch; her arm became itchy; her arm became swollen; her arm became red; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE WARMTH (her arm became warm to the touch), VACCINATION SITE PRURITUS (her arm became itchy), VACCINATION SITE SWELLING (her arm became swollen) and VACCINATION SITE ERYTHEMA (her arm became red) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Feb-2021, the patient experienced VACCINATION SITE WARMTH (her arm became warm to the touch), VACCINATION SITE PRURITUS (her arm became itchy), VACCINATION SITE SWELLING (her arm became swollen) and VACCINATION SITE ERYTHEMA (her arm became red). At the time of the report, VACCINATION SITE WARMTH (her arm became warm to the touch), VACCINATION SITE PRURITUS (her arm became itchy), VACCINATION SITE SWELLING (her arm became swollen) and VACCINATION SITE ERYTHEMA (her arm became red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication and treatment drug were not reported.
pain in shoulders/ Pain continue to migrate to elbow's, hands, wrists and feet; This is a spontaneous report from a contactable consumer (patient). A male patient of unknown age received dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: Solution for injection, lot number and Expiry date: not provided), via unspecified route as dose number unknown, single for COVID-19 immunization. The patient's medical history and concomitant medication was not reported. On an unknown date, the patient experienced pain continued to migrate from shoulders to elbows, hands, wrist and feet not as severe. The outcome of the events were unknown.  No follow up attempts were possible. Information about lot/batch number cannot be requested.
Vision disturbances beginning  about 20 minutes after shot. The rest of the day was followed by extreme light sensitivy, without pain, which resolved the next day. Visual disturbances (vision sometimes blurry, shaky, or glitchy) continued for about 8 days, especially when looking at screens or the lights of traffic. This became accompanied by a jumpy feeling, feeling of fear that I may trigger a seizure, and extreme sensitivity to smells and nausea, strange body sensations. General hard-to-describe feeling of something being off, not painful but scary at times.
Around 24 hours after getting vaccine, I all of a sudden felt like my heart was beating very fast, I could feel it in my throat and I felt short of breath.  I am a nurse so I checked my heart rate with a pulse ox and my heart rate was in the 130's.  I was able to get my heart rate to lower by remaining still and not doing anything for the rest of the day.  If I tried to do any activity, my heart rate would shoot up and I would again feel short of breath.  This lasted throughout the day.  The next day, it was magically gone and my heart rate returned to normal.    I also noticed a few months after receiving the vaccine, my hair started to fall out in large amounts.  This persisted for several months.  I did not lose all my hair but it thinned dramatically, maybe by 50%.  I have noticed in the past few months, it is growing back.   I have no health issues and I do not take any medication.  The vaccine is the only thing I can contribute this to.
High grade fever; 102F fever after the first dose, and 104F fever after the second dose of the COVID vaccine. In both cases, symptoms started about 14-18 hours post-dose, manageable to some extent with acetaminophen.
Pfizer COVID vaccine, symptoms still evolving and mimic COVID but negative COVID test. Have lost ability to walk without a walker, severe weakness, fatigue, dizzy, distortion in hearing, metellic taste, body aches and joint pain, intermittent headache and nausea. No fever no cough.
Dizziness and diaphoresis about 2 hours after vaccine administration.  Local induration, warmth, and pain about 5cm in diameter.
Breakthrough case admission after 2 vaccines Pfizer 4/6/21 lot# ER8730;  Pfizer 4/27/21 lot# ER8730;
Arm and chest pains, difficulty breathing, fatigue, headache, neck ache, upset stomach, sleeplessness. lack of appetite  Treated in the Emergency Room on Sept. 12, 2022 and examined by primary physician in her office on September 21, 2022.
Swollen left upper arm with persistent pain and weekness. The lenth of time is about 3 months which resulted in Doctor visits that accured bills.
Fever; chills; Headache; Tired; Shooting pain behind ears; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 22Apr2021 at 13:30(at the age of 31-year-old) as a single dose for COVID-19 immunisation. Medical history included allergic to mango. Concomitant medications included ethinylestradiol, norethisterone acetate (JUNEL) for unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 09Apr2021 at 13:30 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021 at 06:00 the patient experienced fever, chills, headache, tired and shooting pain behind ears. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event fever, chills, headache, tired and shooting pain behind ears was recovered on an unknown date in Apr2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Muscle Pain; Tiredness; Arm hurts; Shivering; Cold; Fever; This non-serious case was reported by a consumer via call center representative and described the occurrence of shivering in a 62-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 11-APR-2023, the patient received the 1st dose of Shingrix (left arm). On 11-APR-2023, less than a day after receiving Shingrix, the patient experienced shivering (Verbatim: Shivering), coldness (Verbatim: Cold), fever (Verbatim: Fever) and pain in arm (Verbatim: Arm hurts). On 12-APR-2023, the patient experienced muscle pain (Verbatim: Muscle Pain) and tiredness (Verbatim: Tiredness). On 12-APR-2023, the outcome of the shivering was resolved (duration 1 day). The outcome of the coldness was not reported and the outcome of the fever was unknown and the outcome of the muscle pain, tiredness and pain in arm were not resolved.   It was unknown if the reporter considered the shivering, coldness, fever, muscle pain, tiredness and pain in arm to be related to Shingrix.     It was unknown if the company considered the shivering, coldness, fever, muscle pain, tiredness and pain in arm to be related to Shingrix.   Additional Information: GSK Receipt Date:12-APR-2023 The patient reported the case for humself. The patient stated he received Shingrix yesterday(one day before reporting), at his physician's office, and started shivering  last night around 9:30PM until around 2AM this morning(reporting day).  The patient was also had cold last night, and also experienced a fever of unknown duration or temperature.  The patient was experiencing muscle pain and tiredness today and arm still hurts(reporting day). The reporter consented to follo-up with Healthcare professional. The reporter consented to follow-up.